USD
+$0.00
(+0.00%
)At Close (As of Oct 14, 2025)
$172.12M
Market Cap
-
P/E Ratio
-1.83
EPS
$6.50
52 Week High
$2.20
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $2.4M |
Total Revenue | $2.6M |
Cost Of Revenue | $204K |
Costof Goods And Services Sold | $204K |
Operating Income | -$64M |
Selling General And Administrative | $24M |
Research And Development | $43M |
Operating Expenses | $67M |
Investment Income Net | - |
Net Interest Income | $3.4M |
Interest Income | $3.4M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $308K |
Income Before Tax | -$61M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$61M |
Comprehensive Income Net Of Tax | - |
Ebit | -$65M |
Ebitda | -$64M |
Net Income | -$61M |
Field | Value (USD) |
---|---|
Total Assets | $76M |
Total Current Assets | $69M |
Cash And Cash Equivalents At Carrying Value | $22M |
Cash And Short Term Investments | $22M |
Inventory | $173K |
Current Net Receivables | $92K |
Total Non Current Assets | $7M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $2.5M |
Short Term Investments | $45M |
Other Current Assets | $2.1M |
Other Non Current Assets | - |
Total Liabilities | $43M |
Total Current Liabilities | $16M |
Current Accounts Payable | $5.1M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.1M |
Total Non Current Liabilities | $27M |
Capital Lease Obligations | $2.2M |
Long Term Debt | $14M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $17M |
Other Current Liabilities | $5.5M |
Other Non Current Liabilities | $40K |
Total Shareholder Equity | $33M |
Treasury Stock | - |
Retained Earnings | -$310M |
Common Stock | $4K |
Common Stock Shares Outstanding | $37M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$51M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $308K |
Capital Expenditures | $289K |
Change In Receivables | - |
Change In Inventory | -$28K |
Profit Loss | - |
Cashflow From Investment | $13M |
Cashflow From Financing | $29M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$61M |
Field | Value (USD) |
---|---|
Gross Profit | $2.4M |
Total Revenue | $2.6M |
Cost Of Revenue | $204K |
Costof Goods And Services Sold | $204K |
Operating Income | -$64M |
Selling General And Administrative | $24M |
Research And Development | $43M |
Operating Expenses | $67M |
Investment Income Net | - |
Net Interest Income | $3.4M |
Interest Income | $3.4M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $308K |
Income Before Tax | -$61M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$61M |
Comprehensive Income Net Of Tax | - |
Ebit | -$65M |
Ebitda | -$64M |
Net Income | -$61M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Orchestra BioMed Holdings, Inc. is an innovative therapeutic device company based in New Hope, Pennsylvania, focused on developing cutting-edge treatments for cardiovascular diseases. The firm's product portfolio includes advanced medical devices designed to address significant unmet clinical needs, leveraging its proprietary technologies to improve patient outcomes. With a commitment to enhancing the quality of care in cardiology, Orchestra BioMed aims to transform therapeutic approaches and expand access to effective cardiovascular solutions, positioning itself as a leader in the evolving healthcare landscape.